Key Takeaways
- Volkswagen (VOWG) has abandoned its 2026 sales growth forecast, signaling a radical overhaul that includes cutting its model lineup by up to 50% and reducing production capacity by 1 million units annually.
- UniCredit (UCG) is moving closer to a takeover of Commerzbank (CBK) after securing a 48% stake; Commerzbank leadership has expressed openness to constructive dialogue despite previous resistance.
- UK Private Sector activity returned to growth in July, with the Composite PMI hitting a three-month high of 52.1, significantly outperforming market expectations of 49.8.
- Novo Nordisk (NVO) has escalated its legal battle with Eli Lilly (LLY), filing for a preliminary injunction in New Jersey to block "misleading" advertisements for Zepbound and Mounjaro.
Volkswagen Abandons Growth Targets Amid Historic Restructuring
Volkswagen (VOWG) CEO Oliver Blume has warned that the German automaker no longer expects revenue growth in 2026, shifting focus toward a "radical" restructuring plan. The company reported a 9.5% profit slump in the second quarter, with operating profit falling to €3.5 billion. To combat high costs and intensifying competition from China, Blume intends to cut the group's model lineup by as much as half and reduce global production capacity to 9 million vehicles per year, down from the current 10 million.
The restructuring, which could result in up to 100,000 job cuts and the closure of four German factories, has met fierce opposition from labor unions. Despite these challenges, Volkswagen maintained its full-year operating margin forecast of 4.0% to 5.5%. The company cited "unavoidable headwinds" including U.S. tariffs and a sharp decline in profit from the Chinese market as primary drivers for the aggressive pivot.
Banking M&A: Commerzbank Signals Openness to UniCredit Talks
The European banking landscape is bracing for a major shift as UniCredit (UCG) CEO Andrea Orcel announced the bank now holds a 48% stake in Commerzbank (CBK). Following months of resistance, Commerzbank CEO Bettina Orlopp stated the lender is open to dialogue, provided any proposal creates value for all stakeholders. UniCredit is currently awaiting regulatory approval, which could be granted as early as the fourth quarter of 2026, to exercise full control over its German rival.
The potential merger would combine UniCredit’s existing German business, HVB, with Commerzbank to create a dominant player in the Eurozone. However, the deal remains sensitive; German labor representatives have warned that a takeover could lead to 7,000 job losses. The German government, which still holds a 12% stake in Commerzbank, has reportedly softened its stance and is preparing for formal discussions regarding the terms of the acquisition.
UK Economy Rebounds with Surprise PMI Growth
The United Kingdom's private sector saw a robust recovery in July, as the S&P Global Flash UK Services PMI surged to 51.8, far exceeding the 49.4 forecast. This marks the first expansion in three months, driven by a rebound in consumer services and hospitality, partly attributed to the FIFA World Cup and favorable weather. The Manufacturing PMI also showed strength, rising to 52.8 and hitting a 22-month high in output.
Economists noted that easing input price inflation, particularly in fuel and raw materials, has provided a much-needed respite for British firms. The Composite PMI reading of 52.1 suggests the UK economy is gaining momentum under the new administration. This data may influence the Bank of England's upcoming interest rate decision, as cooling price pressures could allow policymakers to maintain the current rate of 3.75%.
Pharma Giants Clash Over Obesity Drug Marketing
Novo Nordisk (NVO) has filed a motion for a preliminary injunction in the U.S. District Court for the District of New Jersey against Eli Lilly (LLY). The lawsuit alleges that Lilly’s advertising for its weight-loss drugs, Zepbound and Mounjaro, uses "intentionally selected outdated studies" to claim superiority over Novo’s Wegovy and Ozempic. Novo Nordisk argues these ads mislead consumers by comparing Lilly’s highest doses against Novo’s lower, less effective doses.
The legal escalation comes as the two pharmaceutical giants compete for dominance in a U.S. obesity market projected to exceed $100 billion by 2030. Novo Nordisk is seeking the immediate removal of the disputed advertisements and a court-mandated corrective campaign. Eli Lilly has denied any wrongdoing, stating it will "vigorously defend" its scientific data and marketing practices in court.
Geopolitical Tension: Kyiv Repels Daytime Attack
Kyiv Mayor Vitali Klitschko reported that air defenses were active on Friday morning to repel a rare daytime Russian ballistic missile attack. The Ukrainian Air Force confirmed the interception of multiple assets, though debris was reported in several city districts. This latest strike follows an intensification of aerial campaigns against the capital, with officials noting an unusually high volume of ballistic and hypersonic missiles used throughout July.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.